Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical <i>Plasmodium</i> Infection Models.

"The authors declare the following competing financial interest(s): D.F., F.A., T.S., C.B., M.P., and P.M.A. are inventors on a patent WO 2018162623. T.H.H.B and T.S. are employees of the healthcare business of Merck KGaA, Darmstadt, Germany, which funded the work and provided novel compounds to be tested in the platforms developed."

"We acknowledge Ana Filipa Teixeira and Ana Parreira for mosquito production and infection. This work was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). M.P. is a recipient of a “Concurso de Estímulo ao Emprego Científico” Principal Investigator award of Fundação para a Ciência e Tecnologia, Portugal (FCT), with ref. N. CEECIND/03539/2017. D.F. is funded by FCT project CRCNA/BRB/0281/2019. F.A. is recipient of a PhD fellowship PD/BD/128371/2017, funded by FCT. Author Contributions: ¶ D.F. and F.A. contributed equally to the work. Conceptualization: D.F., F.A., T.S., C.B., M.P., P.M.A. Methodology: D.F., F.A., I.R.G., G.N., D.M., T.H.H.B. Formal analysis: D.F., F.A., I.R.G., T.H.H.B., C.B., M.P .Writing–original draft: D.F., F.A. Writing–review and editing: T.S., C.B., M.P., P.M.A. Funding acquisition: T.S., M.P., P.M.A. Supervision: T.S., C.B., M.P., P.M.A."